GSK Dutasteride Launch Set With Added BPH Claims, Avodart Name
Executive Summary
GlaxoSmithKline plans to launch its benign prostatic hyperplasia treatment dutasterideunder the brand name Avodart in December
You may also be interested in...
Merck Will Launch New Proscar Indication During Last Week Of April
Merck plans to launch a new indication for the benign prostatic hyperplasia therapy Proscar during the American Urology Association annual meeting April 26-May 1
Merck Will Launch New Proscar Indication During Last Week Of April
Merck plans to launch a new indication for the benign prostatic hyperplasia therapy Proscar during the American Urology Association annual meeting April 26-May 1
GSK Dutasteride sNDA Seeks Urinary Retention, Reduced Surgery Claims
GlaxoSmithKline is seeking claims for reduced risk of acute urinary retention and reduced need for surgery related to benign prostatic hyperplasia in a supplemental NDA filing for dutasteride